TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16684021

Group type: EXPERIMENTAL
Intervention: RF output titrated to avoid microbubble formation (Group I)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard power-limited RF output (Group II)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Group II (Control)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Group I (Intervention)
Number of subjects: 202
Study: 15031590

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Guided support groups
Number of subjects: 270

Group type: COMPARATOR
Intervention: Natural course
Number of subjects: 270

Group type: COMPARATOR
Intervention: Fatigued employees
Number of subjects: 270

Group type: COMPARATOR
Intervention: Disease-free breast cancer patients
Number of subjects: 270

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 270
Study: 11231700

Group type: EXPERIMENTAL
Intervention: Reduced sodium intervention
Number of subjects: 681

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 681
Study: 9038130

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5, 25, or 50 micromol/kg body weight) administered as an IV bolus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA
Number of subjects: 31
Study: 7912123

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 7.5 g every 4 weeks for 1 year
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 40 g every 4 weeks for 1 year
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard HIV treatment (control group)
Number of subjects: 35
Study: 2638869

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1167297

Group type: EXPERIMENTAL
Intervention: Vinblastine alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Prednisone and vinblastine
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Prednisone and 6-mercaptopurine
Number of subjects: 83
Study: 31148302

Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Disruptions in Foster Care Placement
Number of subjects: 142
Study: 31724350

Group type: EXPERIMENTAL
Intervention: Acupuncture at experienced ten acupoints (Baihui, Zhongwan, Qihai, Tianshu, Neiguan, Zusanli, Gongsun, Danzhong)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-acupoint points with shallow puncture
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acupuncture at experienced ten acupoints
Number of subjects: 62
Study: 28554910

Group type: EXPERIMENTAL
Intervention: Twice-daily supportive SMS text messages for 6 months plus treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 0
Study: 26452544

Group type: EXPERIMENTAL
Intervention: Monitoring and recording skin temperatures with theory-based counselling
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard foot care and recording foot inspections
Number of subjects: 41
Study: 24205943

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 22924260

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 0.1 J per point
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 1 J per point
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with energy dose of 4 J per point
Number of subjects: 66
Study: 20651076

Group type: EXPERIMENTAL
Intervention: Serum mesothelin levels in asbestos-exposed individuals
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Increase in mesothelin levels above the 95% confidence interval
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Serum mesothelin as a biomarker
Number of subjects: 314
Study: 18334495

Group type: COMPARATOR
Intervention: No planned distraction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Telephone call distraction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TV show distraction
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computer assignment distraction
Number of subjects: 40
Study: 16162478

Group type: EXPERIMENTAL
Intervention: [11C]-R-PK11195 PET imaging in HIV+ patients with HAD
Number of subjects: 15

Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in nondemented HIV+ patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in overall HIV+ patients (demented and nondemented)
Number of subjects: 15

Group type: COMPARATOR
Intervention: [11C]-R-PK11195 PET imaging in patients with HAD
Number of subjects: 15
Study: 12878619

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg kg(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Morphine (0.1 mg kg(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (2 ml)
Number of subjects: 90
Study: 10381027

Group type: EXPERIMENTAL
Intervention: One interviewer
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Two interviewers
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Two methods (self-completion and interviewer administration)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Change in method of administration
Number of subjects: 487
Study: 9094875

Group type: EXPERIMENTAL
Intervention: Night meal (0100)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Day meal (1300)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control fasting reference line
Number of subjects: 13
Study: 8345080

Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-uterine insemination (IUI)
Number of subjects: 60
Study: 3578852

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine with 1:300,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 ml of 0.25% bupivacaine
Number of subjects: 100
Study: 31674058

Group type: COMPARATOR
Intervention: VIT-2763 5/15/60/120/240 mg (SAD phase)
Number of subjects: 72

Group type: COMPARATOR
Intervention: VIT-2763 60/120 mg once daily (MAD phase)
Number of subjects: 72

Group type: COMPARATOR
Intervention: VIT-2763 60/120 mg twice daily (MAD phase)
Number of subjects: 72

Group type: COMPARATOR
Intervention: VIT-2763 (all doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: VIT-2763 120 mg once daily (MAD phase)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 27893567

Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity home exercise program with 4 additional consults post-discharge (n = 26).
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual ambulatory physical therapy (PT) (n = 43).
Number of subjects: 69
Study: 26293170

Group type: EXPERIMENTAL
Intervention: adapalene gel with the active formulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: adapalene gel with the placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: adapalene gel
Number of subjects: 120
Study: 24119418

Group type: EXPERIMENTAL
Intervention: Educational intervention (e‐magazine addressing health risks of sunbed use)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 22627991

Group type: EXPERIMENTAL
Intervention: Candesartan (7 days treatment)
Number of subjects: 2029
Study: 20522298

Group type: EXPERIMENTAL
Intervention: Breastfeeding with skin-to-skin contact (group 1, n=35)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact without breastfeeding (group 2, n=36)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (lying on the table, group 3, n=36)
Number of subjects: 107
Study: 18482455

Group type: EXPERIMENTAL
Intervention: Bunionectomy, osteotomy, lateralization of the distal fragment, lateral release and medial capsulorrhaphy
Number of subjects: 115
Study: 15912461

Group type: EXPERIMENTAL
Intervention: Green light test at the slit lamp (Haag‐Streit, Switzerland)
Number of subjects: 28

Group type: COMPARATOR
Intervention: WASCA (wave‐front analyser, Carl‐Zeiss‐Meditec)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 28
Study: 12915819

Group type: EXPERIMENTAL
Intervention: Ganciclovir therapy (6 weeks of intravenous ganciclovir)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ganciclovir therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 10574621

Group type: EXPERIMENTAL
Intervention: Neutrophil-derived serine proteases (elastase, cathepsin G, proteinase 3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Elastase
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cathepsin G
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neutrophil-derived serine proteases
Number of subjects: 39
Study: 8635647

Group type: EXPERIMENTAL
Intervention: Nondiabetic African-Americans
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Nondiabetic Hispanics
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 1086
Study: 8299622

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation interventions including physical training, risk factor modifications, and lifestyle changes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directed supervision in cardiac rehabilitation units or clinical conditions during early rehabilitation phase II.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programs initiated in acute phase I, convalescent phase II, and maintenance phase III after myocardial infarction.
Number of subjects: 0
Study: 2935737

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29893769

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg daily for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palbociclib in HR-positive/HER2-negative subgroup
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 100
Study: 27214258

Group type: EXPERIMENTAL
Intervention: Mavoglurant 100 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavoglurant 150 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavoglurant 200 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25823174

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Precede‐Proceed Model
Number of subjects: 510
Study: 22321451

Group type: EXPERIMENTAL
Intervention: Differential outcomes procedure (DOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-differential outcomes condition
Number of subjects: 0
Study: 20167446

Group type: EXPERIMENTAL
Intervention: Cooled water pillow (15 degrees C) for 48 hours with restricted activity and medication (60 mg of prednisone for 7 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group received only medication (60 mg of prednisone for 7 days) without cooling and rest
Number of subjects: 86
Study: 18702908

Group type: EXPERIMENTAL
Intervention: Very low calorie diet with supervised lifestyle intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine lifestyle counseling
Number of subjects: 52
Study: 15913526

Group type: EXPERIMENTAL
Intervention: Zadik procedure
Number of subjects: 83

Group type: COMPARATOR
Intervention: Chemical ablation by sodium hydroxide
Number of subjects: 83
Study: 12566475

Group type: EXPERIMENTAL
Intervention: Protein Group (1.6 g/(kg. d); CHO <40% of energy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CHO Group (0.8 g/(kg. d); CHO >55%)
Number of subjects: 24
Study: 9892860

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.75 mg s.c.)
Number of subjects: 8
Study: 8539603

Group type: EXPERIMENTAL
Intervention: Adaptive training exercises mounted as computer 'games' for 8 to 16 hours during a 20-day period.
Number of subjects: 0
Study: 1912753

Group type: EXPERIMENTAL
Intervention: Naltrexone (350 mg per week for 1 month, then random allocation to naltrexone for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (random allocation for 6 months)
Number of subjects: 50
Study: 6756833

Group type: EXPERIMENTAL
Intervention: 40-g/day vegetable protein diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 80-g/day vegetable protein diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: 40-g/day meat protein diet plus neomycin-milk of magnesia
Number of subjects: 10
Study: 30052800

Group type: EXPERIMENTAL
Intervention: Resistance training and healthy diet rich in N-3 PUFAs (RT-HD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Resistance training only (RT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 63
Study: 28969408

Group type: EXPERIMENTAL
Intervention: TOT (Transobturator Tape)
Number of subjects: 206

Group type: COMPARATOR
Intervention: TOT with cough stress test
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: TOT
Number of subjects: 206
Study: 26111609

Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg, subcutaneous, every 12 h from postoperative day 2 to 8)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IPC (intermittent pneumatic compression, continued until full ambulation)
Number of subjects: 30
Study: 24859203

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 21390056

Group type: EXPERIMENTAL
Intervention: Indapamide slow release 1.5 mg, indapamide plus 2 mg perindopril, and indapamide plus 4 mg perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide plus 2 mg perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide plus 4 mg perindopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study: 19745590

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus paclitaxel (AT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Fluorouracil/doxorubicin/cyclophosphamide (FAC)
Number of subjects: 267
Study: 17688720

Group type: EXPERIMENTAL
Intervention: Calculated intravenous crystalloid based on body weight (group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intravenous fluid (group 1)
Number of subjects: 33
Study: 15449627

Group type: EXPERIMENTAL
Intervention: Elastic cloth paste (including silicone) with Dan‐shen root and azone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Elastic cloth paste (including silicone)
Number of subjects: 301
Study: 11289042

Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 (1.2 pmol x kg(−1) x min(−1))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9647873

Group type: EXPERIMENTAL
Intervention: Transfusions to reduce hemoglobin S concentration to less than 30 percent of total hemoglobin concentration
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130
Study: 8059811

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg three times a day for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2648511

Group type: EXPERIMENTAL
Intervention: Combination of isoniazid, rifampicin, and pyrazinamide (fixed proportions)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Separate tablets of isoniazid, rifampicin, and pyrazinamide
Number of subjects: 250
Study: 5338884

Group type: EXPERIMENTAL
Intervention: Ro 4‐5360, 10 mg. (Mogadon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: methyprylon, 200 mg. (Noludar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ro 4‐5360, 5 mg. (Mogadon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: secobarbital sodium, 100 mg. (Seconal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30939905

Group type: EXPERIMENTAL
Intervention: 12-month exercise programme
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study: 28455295

Group type: EXPERIMENTAL
Intervention: Low stroke volume indexed for body surface area (SVI) defined as <35 mL/m2
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Baseline SVI
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: In-study low SVI
Number of subjects: 1671
Study: 25974325

Group type: EXPERIMENTAL
Intervention: Primary orchiopexy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Two-stage orchiopexy
Number of subjects: 112
Study: 23716516

Group type: EXPERIMENTAL
Intervention: Hydration (drank 250 mL of water at 15‐minute intervals, totaling 1000 mL/h)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 79
Study: 21494161

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 16

Group type: COMPARATOR
Intervention: Miller
Number of subjects: 16
Study: 18356517

Group type: EXPERIMENTAL
Intervention: Subliminal priming with the concept of exertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal primes accompanied by consciously visible positive stimuli
Number of subjects: 0
Study: 16779972

Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied to experimental dental quadrants every 3 months during 12 months of orthodontic treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 10
Study: 14699594

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) treatment for one or two consecutive sessions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) treatment
Number of subjects: 17
Study: 10898125

Group type: EXPERIMENTAL
Intervention: 24-hr sleep deprivation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal sleep periods (NSP)
Number of subjects: 28
Study: 9360001

Group type: EXPERIMENTAL
Intervention: 0.1 mg reserpine plus 5 mg clopamide (R/C)
Number of subjects: 127

Group type: COMPARATOR
Intervention: 5 mg enalapril
Number of subjects: 127
Study: 1541966

Group type: EXPERIMENTAL
Intervention: Intrathecal corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Systemic corticosteroids
Number of subjects: 50
Study: 2879292

Group type: EXPERIMENTAL
Intervention: EPA-rich diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: LA-rich diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: LNA-rich diet
Number of subjects: 0
Study: 30417575

Group type: EXPERIMENTAL
Intervention: TAKE 5 multi-component weight management programme including an energy deficit diet (EDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waist Winners Too based on health education principles
Number of subjects: 0
Study: 29856470

Group type: EXPERIMENTAL
Intervention: Adrecizumab (various doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adrecizumab (1 ng kg-1 h-1) during endotoxaemia
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26666481

Group type: EXPERIMENTAL
Intervention: High TEWL group (TEWL > 6.5 g/m(2)/h)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Daily emollient use in high TEWL group
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High TEWL group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Low TEWL group
Number of subjects: 116
Study: 24657685

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140
Study: 22823856

Group type: EXPERIMENTAL
Intervention: Child plus parent intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Child only intervention
Number of subjects: 88
Study: 18005310

Group type: EXPERIMENTAL
Intervention: Cessation of irrigation before harvesting
Number of subjects: 726
Study: 15615797

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conservative therapy (no-PCI)
Number of subjects: 36
Study: 14969077

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg once a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 10382902

Group type: EXPERIMENTAL
Intervention: recombinant human G‐CSF (rhG‐CSF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ciprofloxacin and amphotericin B (CAB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Median hospitalization duration and costs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 40

Group type: COMPARATOR
Intervention: prophylactic CAB
Number of subjects: 40
Study: 8886213

Group type: EXPERIMENTAL
Intervention: Naprelan 1,000 mg once daily
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg BID
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Naprelan 1,000 mg once daily (open-label phase)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg BID (open-label phase)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo (open-label phase)
Number of subjects: 347
Study: 1999025

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 686

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 686
Study: 6360747

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31342907

Group type: EXPERIMENTAL
Intervention: e-CuidateChemo (Web-based exercise program)
Number of subjects: 68
Study: 29126178

Group type: EXPERIMENTAL
Intervention: Intradialytic pedaling exercise (EX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual hemodialysis (nonEX)
Number of subjects: 20